SCHEMBL22389471

SCHEMBL22389471

CC(C)(C)Cc1c(F)cccc1OC1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PDE4D Q08499 3/20 0.39
▸ PDE4B Q07343 2/20 0.39
▸ PDE4A P27815 2/20 0.39
▸ PDE4C Q08493 1/20 0.39
▸ SLC6A2 P23975 5/20 0.39
▸ SLC6A3 Q01959 3/20 0.39
▸ SLC6A4 P31645 2/20 0.39
▸ CARM1 Q86X55 2/20 0.39
▸ PRMT1 Q99873 2/20 0.39
▸ HTR1A P08908 4/20 0.38
▸ AXL P30530 1/20 0.38
▸ FLT3 P36888 1/20 0.38
▸ MERTK Q12866 1/20 0.38
▸ MCHR1 Q99705 2/20 0.37
▸ RIPK1 Q13546 1/20 0.36
▸ NPY1R P25929 1/20 0.36
▸ NPY2R P49146 1/20 0.36
▸ KAT6A Q92794 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22393187 0.87 SYK (0.42) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL24180099 0.82 PDE4D (0.41) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL22957686 0.82 NPY1R (0.53) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL29786569 0.80 CSNK2A1 (0.44) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL16793239 0.80 CSNK2A1 (0.44) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL22957777 0.79 AXL (0.43) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL22392048 0.77 RIPK1 (0.54) AXLMERTKMCHR1RIPK1
SCHEMBL24018768 0.77 MCHR1 (0.40) PDE4DPDE4BPDE4APDE4CSLC6A2
SCHEMBL22393236 0.77 RIPK1 (0.60) AXLMERTKMCHR1RIPK1
SCHEMBL10190860 0.76 KDM1A (0.43) SLC6A2SLC6A3SLC6A4RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200277296-A1 AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200277296-A1 AMINOIMIDAZOPYRIDAZINES AS KINASE INHIBITORS RIPK1, RIPK4, RIPK3 PDE4D 1763/4885PDE4B 1735/4885PDE4A 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback